Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.43 |
| ▸ | PDE4A | P27815 | 5/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31142175 | 0.81 | ADORA2B (0.44) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL3423318 | 0.79 | ADORA2B (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL30013176 | 0.77 | ADORA2A (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL31392722 | 0.77 | ADORA2B (0.51) | ADORA2BADORA3BLM | |
| SCHEMBL30012368 | 0.76 | ADORA2A (0.43) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL28531664 | 0.76 | ADORA2B (0.57) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL31142206 | 0.76 | ADORA2A (0.47) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL30012879 | 0.75 | ADORA2A (0.47) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL31142180 | 0.74 | ADORA2A (0.41) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL31142181 | 0.74 | ADORA2B (0.47) | ADORA2BADORA3ADORA2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| US-20260055132-A1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187759-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240116974-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-115427063-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-4065155-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055132-A1 | TLR7 AGONISTS | TLR7, TLR8, TLR1 | ADORA2B 612/4885ADORA3 273/4885ADORA2A 452/4885 |
| US-20240116974-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885ADORA2A 280/4885 |
| US-12187759-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885ADORA2A 280/4885 |
| US-11692005-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885ADORA2A 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.